Penester tablets 5mg, No. 30

treatment of benign prostatic hyperplasia (BPH) and prevention of urological complications in order to: reduce the risk of acute urinary retention; reducing the risk of the need for surgical interventions, incl. transurethral resection (TUR) of the prostate and prostatectomy;

treatment to reduce the size of an enlarged prostate gland, improve urination, and reduce symptoms associated with BPH.

in combination with doxazosin to reduce the risk of progression of symptoms associated with BPH.

Inside, 5 mg once a day, regardless of food intake.

The duration of therapy before evaluating its effectiveness should be at least 6 months, so the course of treatment should be long enough. PenesterЃ can be used as monotherapy or in combination with doxazosin.

Liver failure. There is insufficient clinical data on the use of the drug in patients with hepatic impairment.

Renal failure In patients with various stages of renal failure (with a decrease in Cl creatinine to 9 ml / min), dose adjustment is not required, since special studies have not demonstrated any changes in the pharmacokinetic profile of finasteride.

Elderly patients. No dose adjustment is required, although pharmacokinetic studies indicate that the elimination of finasteride in patients over 70 years of age is somewhat reduced.

hypersensitivity to any of the components of the drug;

patients with rare hereditary lactose intolerance, lactase deficiency or impaired absorption of glucose-galactose should not take this drug;

pregnancy and use of the drug in women of childbearing age (see 'Use during pregnancy and lactation');

age up to 18 years.

With caution: patients with a large volume of residual urine and / or a significantly reduced urinary flow rate; liver failure; old age.